Skip to main content

Table 2 Baseline patients, tumors and treatment characteristics

From: Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking

Age

 Median

77

Range [63–81]

Comorbidities

 None

4 (30.7%)

 

 1 Comorbidity

4 (30.7%)

 

  > 1 Comorbidities

5 (38.6%)

 

Anticoagulants

 Yes

5 (38.6%)

 

 No

8 (61.4%)

 

Alpha blockers

 Yes

5 (38.6%)

 

 No

8 (61.4%)

 

IPSS

 Median

8

Range [2–14]

Prostate volume (mL)

 Median

35.5

Range [24–80]

NCCN risk group

 Intermediate unfavorable

7 (69.2%)

 

 High

3 (23.1%)

 

 Very High

1 (7.7%)

 

Gleason score

 7 (4 + 3)

9 (69.2%)

 

 8 (4 + 4)

2 (15.4%)

 

 9 (4 + 5)

1 (7.7%)

 

 10 (5 + 5)

1 (7.7%)

 

ISUP grading group

 3

9 (69.2%)

 

 4

2 (15.4%)

 

 5

2 (15.4%)

 

Clinical stage

 T2a

4 (30.8%)

 

 T2b

2 (15.4%)

 

 T2c

6 (46.1%)

 

 T3a

1 (7.7%)

 

PSA level (mg/mL)

 Median

9.78

Range [4.99–20]

  < 10

8 (61.4%)

 

 10–20

5 (38.6%)

 

Radiation therapy prescribed and delivered

 40 Gy in 5 fractions

4 (30.8%)

 

 38 Gy in 4 fractions

9 (69.2%)

 

CTV (cc)

 Median

47.05

Range [32.06–96.71]

PTV (cc)

 Median

66.60

Range [48.89–128.53]

PTV (D95)

 Median

96%

Range [95–97%]